NICE says ‘yes’ to new option for rheumatoid arthritis

NICE recommends RoActemra® (tocilizumab) as monotherapy for treatment of severe rheumatoid arthritis

Source: Pharmacy Europe - September 4, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Guidelines Legislation & regulation Rheumatology Patient care ADACTA anti-TNF monotherapy cDMARDs Latest News nice rheumatoid arthritis roactemra severe RA tocilizu Source Type: news